Abstract
Understanding what triggers hypermethylation of tumour suppressor genes in cancer cells is critical if we are to discern the role of methylation in the oncogenic process. CpG sites in CpG island promoters, that span most tumour suppressor genes, remain unmethylated in the normal cell, despite the fact that CpG sites are the prime target for de novo methylation by the DNA methyltransferases. The CpG island-associated with the GSTP1 gene is an intriguing example of a CpG rich region which is susceptible to hypermethylation in the majority of prostate tumours and yet is unmethylated in the normal prostate cell. In this study we evaluate a number of factors purported to be involved in hypermethylation to test their role in triggering hypermethylation of GSTP1 in prostate cancer DU145 and LNCaP cells. We find that hypermethylation is not associated with (1) elevated expression of the DNA methyltranferases, or (2) removal of Sp1 transcription factor binding sites in the CpG island or (3) removal of CpG island boundary elements or (4) prior gene silencing. Instead our results support a model that requires a combination of prior gene silencing and random ‘seeds’ of methylation to trigger hypermethylation of the GSTP1 gene in the prostate cancer cell. We propose that the GSTP1 gene is initially silenced in the prostate cancer and random sites of methylation accumulate that result in subsequent hypermethylation and chromatin remodelling.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Baylin SB, Esteller M, Rountree MR, Bachman KE, Schuebel K, Herman JG . 2001 Hum. Mol. Genet. 10: 687–692
Bird AP, Wolffe AP . 1999 Cell 99: 451–454
Brandeis M, Frank D, Keshet I, Siegfried Z, Mendelsohn M, Nemes A, Temper V, Razin A, Cedar H . 1994 Nature 371: 435–438
Brooks JD, Weinstein M, Lin XH, Sun YH, Pin SS, Bova GS, Epstein JI, Isaacs WB, Nelson WG . 1998 Cancer Epidemiol. Biomarkers Prev. 7: 531–536
Clark SJ, Frommer M . 1995 DNA and Nucleoprotein Structure, In Vivo Saluzand HP and Wiebauer K (eds) Springer-Verlag, Austin, Texas: RG Landes Company pp 123–132
Clark SJ, Harrison J, Paul CL, Frommer M . 1994 Nucleic Acids Res. 22: 2990–2997
Cookson MS, Reuter VE, Linkov I, Fair WR . 1997 J. Urology 157: 673–676
Costello JF, Plass C . 2001 J. Med. Genet. 38: 285–303
Cowell IG, Dixon KH, Pemble SE, Ketterer B, Taylor JB . 1988 Biochem J. 255: 79–83
Eads CA, Danenberg KD, Kawakami K, Saltz LB, Danenberg PV, Laird PW . 1999 Cancer Res. 59: 5860–
Esteller M . 2000 Eur. J. Cancer 36: 2294–2300
Esteller M, Corn PG, Urena JM, Gabrielson E, Baylin SB, Herman JG . 1998 Cancer Res. 58: 4515–4518
Hsieh CL . 1999 Mol. Cell Biol. 19: 8211–8218
Huschtscha LI, Noble JR, Neumann AA, Moy EL, Barry P, Melki JR, Clark SJ, Reddel RR . 1998 Cancer Res. 58: 3508–3512
Jhaveri MS, Morrow CS . 1998 Gene 210: 1–7
Jones PA, Laird PW . 1999 Nat. Genet. 21: 163–167
Jost J-P, Frémont M, Siegmann M, Hofsteenge J . 1997 Nucleic Acids Res. 25: 4545–4550
Kass SU, Pruss D, Wolffe AP . 1997 Trends Genet. 13: 444–449
Kuzmin I, Geil L, Ge HY, Bengtsson U, Duh FM, Stanbridge EJ, Lerman MI . 1999 Oncogene 18: 5672–5679
Lee W-H, Morton RA, Epstein JI, Brooks JD, Campbell PA, Bova GS, Hsieh W-S, Isaacs WB, Nelson WG . 1994 Proc. Natl. Acad. Sci. USA 91: 11733–11737
Li E, Bestor TH, Jaenisch R . 1992 Cell 69: 915–926
Macleod D, Charlton J, Mullins J, Bird AP . 1994 Genes Dev. 8: 2282–2292
Marin M, Karis A, Visser P, Grosveld F, Philipsen S . 1997 Cell 89: 619–628
Melki JM, Vincent PC, Clark SJ . 1999 Cancer Res. 59: 3730–3740
Melki JR, Vincent PC, Brown RD, Clark SJ . 2000 Blood 95: 3208–3213
Millar DS, Ow KK, Paul CL, Russell PJ, Molloy PL, Clark SJ . 1999 Oncogene 18: 1313–1324
Millar DS, Paul CL, Molloy PL, Clark SJ . 2000 J. Biol. Chem. 275: 24893–24899
Moffat GJ, McLaren AW, Wolf CR . 1996a J. Biol. Chem. 271: 20740–20747
Moffat GJ, McLaren AW, Wolf CR . 1996b J. Biol. Chem. 271: 1054–1060
Moskaluk CA, Duray PH, Cowan KH, Linehan M, Merino MJ . 1997 Cancer 79: 1595–1599
Okano M, Bell DW, Haber DA, Li E . 1999 Cell 99: 247–257
Rhee I, Jair KW, Yen RW, Lengauer C, Herman JG, Kinzler KW, Vogelstein B, Baylin SB, Schuebel KE . 2000 Nature 404: 1003–1007
Robertson KD, Uzvolgyi E, Liang G, Talmadge C, Sumegi J, Gonzales FA, Jones PA . 1999 Nucleic Acids Res. 27: 2291–2298
Tchou JC, Lin XH, Freije D, Isaacs WB, Brooks JD, Rashid A, DeMarzo AM, Kanai Y, Hirohashi S, Nelson WG . 2000 Int. J. Oncol. 16: 663–676
Thalmann GN, Sikes RA, Chang SM, Johnston DA, von Eschenbach AC, Chung LW . 1996 J. Natl. Cancer Inst. 88: 794–801
Turker MS, Bestor TH . 1997 Mutat Res. Rev. 386: 119–130
Vertino PM, Yen RW, Gao J, Baylin SB . 1996 Mol. Cell. Biol. 16: 4555–4565
Warnecke P, Clark S . 1998 PhD thesis DNA Methylation in Early Development University of Sydney, Sydney
Warnecke PM, Clark SJ . 1999 Mol. Cell. Biol. 19: 164–172
Wong DJ, Barrett MT, Stoger R, Emond MJ, Reid BJ . 1997 Cancer Res. 57: 2619–2622
Acknowledgements
We are grateful to Dr P Molloy from CSIRO Molecular Science, Sydney for helpful discussions and for the gift of pCI-GFP. We thank Dr P Board, from JCSMR Canberra, for the gift of Cosmid cosGSTpP6. J Song and C Stirzaker contributed equally to the manuscript and are supported by NH&MRC grant (9937987) and JR Melki is funded by an Anthony Rothe Memorial Trust grant.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Song, J., Stirzaker, C., Harrison, J. et al. Hypermethylation trigger of the glutathione-S-transferase gene (GSTP1) in prostate cancer cells. Oncogene 21, 1048–1061 (2002). https://doi.org/10.1038/sj.onc.1205153
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205153